Ranbaxy Gets FDA Approval for Insomnia Drug

by VR Sreeraman on  March 17, 2007 at 2:12 PM Drug News   - G J E 4
Ranbaxy Gets FDA Approval for Insomnia Drug
Indian drug major Ranbaxy Laboratories Ltd says it has obtained tentative approval from the US Food and Drug Administration to manufacture and market a drug for insomnia.

The US unit of the company announced Friday that the Office of Generic Drugs, US FDA, has determined the Ranbaxy formulations of Zolpidem Tartrate tablets to be bioequivalent and to have the same therapeutic effect as that of Ambien tablets of Sanofi Aventis US, LLC.

Zolpidem Tartrate tablets are indicated for the short-term treatment of insomnia and related disorders. As per latest data, the total annual market sales for Zolpidem Tartrate tablets were $2.12 billion.

Ranbaxy said the new drug would be manufactured at the company's Ohm Laboratories Inc. facility, based in North Brunswick, New Jersey, USA.

The vice president of sales and marketing of Ranbaxy Pharmaceuticals Inc., USA, Jim Meehan, said that the product would be launched following final approval from the FDA. This would give yet another opportunity for Ranbaxy to expand its product portfolio by offering an affordable generic alternative, he added.

The Jacksonville, Florida-based Ranbaxy Pharmaceuticals Inc. is a wholly owned subsidiary of the company. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

Source: IANS

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All